Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>In Vitro</i> Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of <i>Staphylococcus</i> spp. and <i>Enterococcus</i> spp

23 Mar 2010

Abstract excerpt

Fidaxomicin (formerly OPT-80) is a narrow-spectrum investigational, nonabsorbed oral agent being developed for the treatment of Clostridium difficile infection (CDI), which is not uncommon among hospitalized patients, resulting in longer hospital stays and increased medical care costs and mortality (2, 6, 7, 9-13, 15, 16). Current CDI therapies are compromised by high recurrence rates and risk of selection for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Resistance in Staphylococcus
Share to Bacterial Identification and Susceptibility Testing
Share to Clostridium difficile and Clostridium perfringens research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20308391
DOI: 10.1128/aac.00090-10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>In Vitro</i> Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of <i>Staphylococcus</i> spp. and <i>Enterococcus</i> sppPMID 20308391Read ↗

<i>In vivo</i> efficacy of fidaxomicin against <i>rpoB</i> mutant <i>Clostridioides difficile</i> infectionSemantic proximity Read ↗

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CDSemantic proximity Read ↗

Clinical and pharmacoeconomic evaluation of fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infectionSemantic proximity Read ↗

Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Semantic proximity Read ↗

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficileSemantic proximity Read ↗

Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficileSemantic proximity Read ↗

Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.Semantic proximity Read ↗

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to FidaxomicinSemantic proximity Read ↗

<i>In Vitro</i> and <i>In Vivo</i> Antibacterial Activities of Omadacycline, a Novel AminomethylcyclineSemantic proximity Read ↗

In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.Semantic proximity Read ↗

Basis of narrow-spectrum activity of fidaxomicin on gut pathogen <i>Clostridioides difficile</i>Semantic proximity Read ↗

Microbiome impact of ibezapolstat and other <i>Clostridioides difficile</i> infection relevant antibiotics using humanized miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.